SLC6A19-IN-4

SLC6A19-IN-4 is an allosteric competitive and orally active B0AT1 (SLC6A19) inhibitor. SLC6A19-IN-4 exhibits inhibitory activity against both human and mouse B0AT1, with corresponding IC50 values of 513 nM and 295 nM, respectively. In addition, SLC6A19-IN-4 also shows excellent metabolic stability. Its main mechanism of action is the dual inhibition of B0AT1 in the intestines (reducing phenylalanine absorption) and kidneys (promoting phenylalanine excretion), thereby significantly increasing the excretion of phenylalanine (Phe) in urine and decreasing the level of phenylalanine in plasma. Based on the above characteristics, SLC6A19-IN-4 can be used in the research of phenylketonuria (PKU) and other diseases related to SLC6 family transporters .